Takeda

At #AADInnovation2026, we presented new data from two pivotal Phase 3 studies of our investigational oral treatment for people with moderate-to-severe plaque #psoriasis, including results across high-impact sites. Read more here: https://lnkd.in/e3-FZ58G

To help create a healthier world for patients and the communities where we operate, we are working to reduce our environmental footprint. We are taking decisive action with ambitious, science-based targets to reach net-zero emissions across our value chain by FY2040. Learn more about the actions that are helping us make progress in our Annual Integrated Report: https://lnkd.in/ejgrpHG4

Everything we do starts with a shared goal: creating better possibilities for patients. No matter our role, we each contribute to that mission. Whether we're advancing research, applying data and AI, supporting manufacturing or leading projects, our work comes together to help make an impact for the people we serve. Discover how our teams turn innovation into impact for patients: https://bit.ly/4bOkOVR #TeamTakeda #GlobalCareers #BioPharmaHiring #LifeSciences

From a single molecule to a potentially life-changing therapy, drug development is a journey of discovery, precision and teamwork. Our Oncology teams connect science and data every step of the way to help bring new possibilities to patients faster. Explore how innovation comes to life and the scientists making it happen: https://bit.ly/4w0b0QN #TeamTakeda #Oncology #Innovation

From expanding into new functions to developing leadership skills and global perspectives, growth here is supported through collaboration, learning and shared purpose.   Hear from employees across the organization as they reflect on the experiences that continue shaping their careers.   Learn more about Takeda careers: https://lnkd.in/ekCx9G6f   #TeamTakeda #MakeHistoryChangeFutures #BioPharmaHiring #LifeSciences

Today we announced a landmark collaboration with the Indonesian Government to strengthen the global plasma ecosystem and expand access to plasma-derived medicinal products (PDMPs) for patients in Indonesia and around the world. This collaboration reflects Takeda’s commitment to supporting healthcare resilience, securing sustainable plasma supply and meeting the growing global need for these life-transforming therapies. We look forward to working closely with the Indonesian government on building long-term capabilities that could benefit patients, communities and the broader healthcare system. Learn more: https://lnkd.in/e4PkY4cg

We’re excited to participate at the International Society on Thrombosis and Haemostasis (ISTH) congress in France. Stop by Booth 906 to explore our commitment to meet evolving patient needs in rare hematology and discover educational opportunities, including: - A von Willebrand disease (#VWD) presentation theater - A VWD and congenital thrombotic thrombocytopenic purpura (#cTTP) symposium - Poster and oral communication presentations See you in Paris! #ISTH2026 #thombosis #hemostasis #rarediseases

The healthcare sector accounts for approximately 8.5%* of U.S. greenhouse gas emissions. Through our first-of-its-kind collaboration with Boston Medical Center (BMC) to reduce emissions and waste, BMC uncovered that most waste that is being processed as hazardous does not need to be. Given the costly and emissions-intensive nature of hazardous waste processing, improved sorting systems represent a practical, near-term opportunity to reduce BMC's environmental footprint. Listen to Christopher Concalo, PharmD, BCPS, from BMC, share insights and learnings from the first-year results. *source: National Academy of Medicine

This year’s VWD CONNECT FOUNDATION INC National Severe Von Willebrand Disease (#VWD) Patient Conference, marked a special time for celebration as we gathered with the community to honor the organization’s 10th annual meeting and the tremendous progress made in the 100 years since the first mention of VWD in medical literature. We are grateful to take part as the community comes together to raise awareness, share perspectives and support patients and families. While we continue to foster education on VWD, it’s equally important to encourage self-advocacy. That’s why we handed out advocacy journals – a practical tool to help patients track every bleed and have more informed conversations with their physicians. Every bleed matters, and together, we can continue to educate on bleeding disorders like VWD because patients deserve answers and a path forward to a brighter future. Learn more about our focus in VWD: https://lnkd.in/evvGYqAP

Immune thrombocytopenia (ITP) is a rare immune-mediated bleeding disorder characterized by low platelet counts, which can increase the risk of bruising and bleeding. For many people living with ITP, the physical and emotional burden can affect daily activities and overall well-being. We look forward to joining the global thrombosis and hemostasis community for #ISTH2026 to deepen our understanding of this rare bleeding disorder.